Debra Bernstein

1.1k total citations
22 papers, 282 citations indexed

About

Debra Bernstein is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Debra Bernstein has authored 22 papers receiving a total of 282 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cardiology and Cardiovascular Medicine, 9 papers in Surgery and 9 papers in Internal Medicine. Recurrent topics in Debra Bernstein's work include Acute Myocardial Infarction Research (18 papers), Antiplatelet Therapy and Cardiovascular Diseases (10 papers) and Venous Thromboembolism Diagnosis and Management (9 papers). Debra Bernstein is often cited by papers focused on Acute Myocardial Infarction Research (18 papers), Antiplatelet Therapy and Cardiovascular Diseases (10 papers) and Venous Thromboembolism Diagnosis and Management (9 papers). Debra Bernstein collaborates with scholars based in United States, Germany and France. Debra Bernstein's co-authors include Efthymios Deliargyris, Arnoud W.J. van ‘t Hof, Philippe Gabríel Steg, Roxana Mehran, Gregg W. Stone, Peter Clemmensen, Jurriën M. ten Berg, Prodromos Anthopoulos, Uwe Zeymer and Martial Hamon and has published in prestigious journals such as Journal of the American College of Cardiology, Journal of Hepatology and The American Journal of Cardiology.

In The Last Decade

Debra Bernstein

21 papers receiving 270 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Debra Bernstein United States	10	255	126	86	41	30	22	282
Félix Damas de los Santos Mexico	6	103 0.4×	70 0.6×	71 0.8×	27 0.7×	29 1.0×	21	180
Thomas Waggoner United States	7	121 0.5×	85 0.7×	105 1.2×	57 1.4×	21 0.7×	14	197
Guido Vittori Italy	8	266 1.0×	78 0.6×	253 2.9×	39 1.0×	83 2.8×	14	345
Evren Kaynak Türkiye	4	199 0.8×	49 0.4×	92 1.1×	107 2.6×	18 0.6×	7	216
Ali Emrah Oğuz Türkiye	6	187 0.7×	44 0.3×	90 1.0×	114 2.8×	15 0.5×	11	215
Laurent Fauchier France	7	253 1.0×	43 0.3×	60 0.7×	96 2.3×	52 1.7×	14	276
Daniel Pontal France	4	156 0.6×	202 1.6×	40 0.5×	18 0.4×	7 0.2×	7	262
Kazuo Misumi Japan	6	129 0.5×	45 0.4×	109 1.3×	27 0.7×	66 2.2×	14	185
Pierre Michel France	4	427 1.7×	46 0.4×	122 1.4×	160 3.9×	41 1.4×	10	453
Rob A. Patrawala United States	18	1.0k 4.1×	98 0.8×	52 0.6×	33 0.8×	57 1.9×	27	1.1k

Countries citing papers authored by Debra Bernstein

Since Specialization

Citations

This map shows the geographic impact of Debra Bernstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra Bernstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra Bernstein more than expected).

Fields of papers citing papers by Debra Bernstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra Bernstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra Bernstein. The network helps show where Debra Bernstein may publish in the future.

Co-authorship network of co-authors of Debra Bernstein

This figure shows the co-authorship network connecting the top 25 collaborators of Debra Bernstein. A scholar is included among the top collaborators of Debra Bernstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra Bernstein. Debra Bernstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vos, G.A., Thomas McAndrew, Philippe Gabríel Steg, et al.. (2017). Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials. American Heart Journal. 194. 73–82. 13 indexed citations

Rakowski, Tomasz, Dariusz Dudek, Arnoud W.J. van ‘t Hof, et al.. (2017). Impact of acute infarct-related artery patency before percutaneous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention in the EUROMAX trial. European Heart Journal Acute Cardiovascular Care. 7(6). 514–521. 6 indexed citations

Grebely, Jason, Ira M. Jacobson, Zeid Kayali, et al.. (2017). SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy. Journal of Hepatology. 66(1). S513–S514. 11 indexed citations

Huber, Kurt, Grégory Ducrocq, Christian W. Hamm, et al.. (2017). Early clinical outcomes as a function of use of newer oral P2Y₁₂ inhibitors versus clopidogrel in the EUROMAX trial. Open Heart. 4(2). e000677–e000677. 3 indexed citations

Fabris, Enrico, Arnoud W.J. van ‘t Hof, Jurriën M. ten Berg, et al.. (2017). One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction. JAMA Cardiology. 2(7). 791–791. 13 indexed citations

Giustino, Gennaro, Roxana Mehran, Sameer Bansilal, et al.. (2016). Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. The American Journal of Cardiology. 118(1). 6–16. 6 indexed citations

Belle, Éric Van, Christian Hengstenberg, Thierry Lefèvre, et al.. (2016). Cerebral Embolism During Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology. 68(6). 589–599. 35 indexed citations

Hengstenberg, Christian, Gennaro Giustino, Thierry Lefèvre, et al.. (2016). MAJOR VASCULAR COMPLICATIONS IN PATIENTS UNDERGOING TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT WITH BIVALIRUDIN OR UNFRACTIONATED HEPARIN: FROM THE EFFECT OF BIVALIRUDIN ON AORTIC VALVE INTERVENTION OUTCOMES (BRAVO) TRIAL. Journal of the American College of Cardiology. 67(13). 4–4.

Dangas, George, Mikkel Malby Schoos, Philippe Gabríel Steg, et al.. (2016). Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment–Elevation Myocardial Infarction. Circulation Cardiovascular Interventions. 9(5). e003272–e003272. 13 indexed citations

10.

Hof, Arnoud W.J. van ‘t, Jurriën M. ten Berg, Uwe Zeymer, et al.. (2016). Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trial. International Journal of Cardiology. 211. 119–123. 7 indexed citations

11.

Ducrocq, Grégory, Philippe Gabríel Steg, Arnoud W.J. van ‘t Hof, et al.. (2016). Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials. European Heart Journal Acute Cardiovascular Care. 6(7). 659–665. 14 indexed citations

12.

Stone, Gregg W., Roxana Mehran, Patrick Goldstein, et al.. (2015). Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 65(1). 27–38. 45 indexed citations

13.

Clemmensen, Peter, Sebastian Wiberg, Arnoud W.J. van ‘t Hof, et al.. (2015). Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 8(1). 214–220. 58 indexed citations

14.

Hof, Arnoud W.J. van ‘t, Francesco Giannini, Jurriën M. ten Berg, et al.. (2015). ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMAX ST-segment resolution substudy. European Heart Journal Acute Cardiovascular Care. 6(5). 404–411. 3 indexed citations

15.

Clemmensen, Peter, Arnoud W.J. van ‘t Hof, Efthymios Deliargyris, et al.. (2014). PREDICTORS ASSOCIATED WITH ACUTE STENT THROMBOSIS AFTER PRIMARY PCI: THE EUROMAX TRIAL. Journal of the American College of Cardiology. 63(12). A27–A27. 7 indexed citations

16.

Geisler, Tobias, Karin Müller, Athanasios Karathanos, et al.. (2014). Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. EuroIntervention. 10(1). 97–104. 2 indexed citations

17.

Steg, Philippe Gabríel, Roxana Mehran, Patrick Goldstein, et al.. (2014). BIVALIRUDIN VERSUS HEPARIN WITH OR WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A POOLED ANALYSIS OF PATIENT-LEVEL DATA FROM THE HORIZONS-AMI AND EUROMAX TRIALS. Journal of the American College of Cardiology. 63(12). A34–A34. 1 indexed citations

18.

Huber, Kurt, Christian W. Hamm, Arnoud W.J. van ‘t Hof, et al.. (2014). IMPACT OF P2Y12 INHIBITOR CHOICE ON 30-DAY OUTCOMES AFTER PRIMARY PCI: AN ANALYSIS FROM THE EUROMAX TRIAL. Journal of the American College of Cardiology. 63(12). A100–A100. 1 indexed citations

19.

Hamon, Martial, Stefano Galli, Kurt Huber, et al.. (2014). Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry. International Journal of Cardiology. 173(2). 290–294. 6 indexed citations

20.

Campbell, Charles L., Steven R. Steinhubl, W. Craig Hooper, et al.. (2010). Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. Journal of Thrombosis and Thrombolysis. 31(2). 139–145. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact